Immunohistochemistry analysis of MAP1B expression in TNBC cell lines and breast cancer patients’ tissues. (A) Immunohistochemistry of MAP1B in TNBC and non-TNBC cell lines. Scale bars, 50 μm. (B) Quantification of MAP1B-expressing cells in breast cancer patients’ tissues. Based on MAP1B expression levels, the cells in breast cancer patients’ tissues were categorized into four classes (negative, 1+, 2+, and 3+; see Fig. 1 C) and counted by QuPath Quantitative Pathology & Bioimaging Analysis software. (C) Immunohistochemistry of MAP1B in breast cancer patients’ tissues. Patients of ID IN01 to IN06 are TNBC, while ones of ID IN07 to IN11 are non-TNBC (lumina). IN04 and IN07 are also shown in Fig. 1 C as representatives of TNBC and luminal, respectively. Scale bars, 100 μm. (D) Kaplan–Meier plots of patients with breast cancer with a MAP1S level. Upper: All subtypes. Lower: TNBC. Datasets were from the KM plotter breast cancer database. HR indicates a hazard ratio. P-values were determined using a log-rank test.